UQ
UQ1.F uniQure N.V
- Market cap
- EUR 1.54B
- P/E
- -
- P/B
- 5.77x
- ROE
- -88.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is UQ1.F undervalued?
Graham numberThe Graham number of uniQure N.V cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
uniQure N.V fundamental analysis
No fundamental analysis for uniQure N.V yet.
uniQure N.V stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About uniQure N.V
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the …
Full company profileuniQure N.V financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
uniQure N.V annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 25.1M | 13.1M | 11.3M | 7.28M | 37.5M | 524M | 106M | 15.8M | 27.1M | 16.1M | 19.5M |
| Gross Profit | - | - | - | - | 37.5M | 499M | 103M | 2.22M | 8.79M | 14.4M | 18.4M |
| Operating Income | -71.9M | -71.3M | -88.2M | -121M | -125M | 311M | -143M | -282M | -182M | -188M | -190M |
| EBITDA | - | -69.7M | -68.5M | -114M | -127M | 348M | -108M | -253M | -161M | -117M | -182M |
| Net Income | -73.4M | -79.3M | -83.3M | -124M | -125M | 330M | -127M | -308M | -240M | -199M | -261M |
| EPS | - | -2.53 | -2.23 | -2.84 | -2.79 | 7.12 | -2.70 | -6.45 | -4.89 | -3.18 | -3.73 |
| Balance Sheet | |||||||||||
| Total Assets | 190M | 210M | 274M | 449M | 340M | 809M | 705M | 832M | 557M | 825M | 941M |
| Total Liabilities | 127M | 120M | 94.3M | 126M | 96.5M | 213M | 229M | 624M | 563M | 626M | 646M |
| Shareholders' Equity | 63.6M | 89.4M | 180M | 323M | 244M | 596M | 476M | 208M | -6.75M | 199M | 295M |
| Cash & Short-term Investments | 132M | 159M | 235M | 378M | 245M | 556M | 228M | 241M | 159M | 80.2M | 98.4M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -72.2M | -64.3M | -76.0M | -98.7M | -135M | 288M | -145M | -146M | -183M | -178M | -153M |
| Capital Expenditure | 17.2M | 4.46M | 2.38M | 5.65M | 7.27M | 17.4M | 17.7M | 7.15M | 11.7M | 439K | 831K |
| Free Cash Flow | - | -69.9M | -80.3M | -105M | -144M | 271M | -163M | -153M | -194M | -178M | -154M |
| Ratios | |||||||||||
| ROE | -115.3% | -88.7% | -46.4% | -38.4% | -51.3% | 55.3% | -26.6% | -148.5% | - | -100.0% | -88.6% |
| ROA | -38.6% | -37.8% | -30.4% | -27.7% | -36.7% | 40.7% | -18.0% | -37.1% | -43.0% | -24.1% | -27.8% |
| Net Profit Margin | -292.3% | -604.7% | -738.2% | -1,705.8% | -333.3% | 62.9% | -119.1% | -1,947.1% | -883.4% | -1,236.0% | -1,341.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
uniQure N.V dividends
uniQure N.V has not paid dividends in the last 9 fiscal years.
Who owns uniQure N.V
- Insiders 1.26%
- Institutions 95.87%
- Public & others 2.87%
- Shares outstanding 70.1M
- Free float 58.3M
uniQure N.V company profile
- Company name
- uniQure N.V
- Ticker
- UQ1.F
- ISIN
- NL0010696654
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 221
- Fiscal year end
- December
- Address
- Paasheuvelweg 25, Amsterdam, Netherlands, 1105 BP
- Phone
- 31 20 240 6000
- Website
- uniqure.com
About uniQure N.V
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
uniQure N.V management
10- Mr. Matthew Craig Kapusta CPACEO & Executive Director · born 1972
- Mr. Christian KlemtCFO, Principal Financial Officer & GM of Amsterdam Site · born 1973
- Dr. Jeannette Potts J.D., Ph.D.Chief Legal & Compliance Officer and Corporate Secretary · born 1962
- Dr. Walid Abi-Saab M.D.Chief Medical Officer · born 1965
- Prof. Hugo KatusChairman of Scientific Advisory Board and Managing Director of UniQure-Germany
- Dr. Amin Abujoub Ph.D.Chief Technical Operations Officer
- Mr. Richard Porter Ph.D.Chief Business & Scientific Officer · born 1968
- Ms. Chiara Elizabeth RussoSenior Director of Investor Relations
- Dr. Tamara Tugal Ph.D., MBABusiness Development Director
- Ms. Erin BoyerChief People & Culture Officer